183 related articles for article (PubMed ID: 36119082)
1. Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review.
Lai KC; Hsiao YH; Chen SC
Front Immunol; 2022; 13():994064. PubMed ID: 36119082
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K
Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.
Camard M; Besse B; Cariou PL; Massayke S; Laparra A; Noel N; Michot JM; Ammari S; Pavec JL; Lambotte O
Respir Med Res; 2022 Nov; 82():100969. PubMed ID: 36370683
[TBL] [Abstract][Full Text] [Related]
4. Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
Ogusu S; Harutani Y; Tozuka T; Saito R; Koyama J; Sakamoto H; Sonoda T; Tsuchiya-Kawano Y; Oba T; Kudo K; Gyotoku H; Nakatomi K; Ariyasu R
Cancer Immunol Immunother; 2023 Nov; 72(11):3765-3772. PubMed ID: 37638979
[TBL] [Abstract][Full Text] [Related]
5. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
[TBL] [Abstract][Full Text] [Related]
6. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.
Beattie J; Rizvi H; Fuentes P; Luo J; Schoenfeld A; Lin IH; Postow M; Callahan M; Voss MH; Shah NJ; Betof Warner A; Chawla M; Hellmann MD
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33568350
[TBL] [Abstract][Full Text] [Related]
7. The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis.
Asada M; Mikami T; Niimura T; Zamami Y; Uesawa Y; Chuma M; Ishizawa K
Oncology; 2021; 99(4):256-259. PubMed ID: 33477139
[TBL] [Abstract][Full Text] [Related]
8. Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis.
Park C; Keam B; Yoon SH; Ock CY; Choi SM; Kim M; Park YS; Kim TM; Oh DY; Kim DW; Kim YW; Heo DS; Bang YJ
ESMO Open; 2019; 4(6):e000575. PubMed ID: 31803501
[TBL] [Abstract][Full Text] [Related]
9. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
[TBL] [Abstract][Full Text] [Related]
10. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
11. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.
Wang W; Wang Q; Xu C; Li Z; Song Z; Zhang Y; Cai X; Zhang S; Lian B; Li W; Liu A; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Xie C; Zhang J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Lan F; Feng H; Wang L; Yao W; Shi X; Huang J; Chen H; Zhang Y; Sun P; Wan B; Pang F; Xu Z; Wang K; Xia Y; Ye M; Wang D; Wei Q; Feng S; Zhou J; Zhang J; Lv D; Gao W; Kang J; Yu G; Liang X; Yu C; Shi L; Yang N; Wu L; Hong Z; Hong W; Fang M; Zhang Y; Lu Y; Wang G; Ma S; Si L; Fang W; Song Y
Thorac Cancer; 2022 Dec; 13(23):3420-3430. PubMed ID: 36268845
[TBL] [Abstract][Full Text] [Related]
12. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer.
Tan P; Huang W; He X; Lv F; Cui Y; Du S
J Immunother; 2023 Feb-Mar 01; 46(2):64-73. PubMed ID: 36637978
[TBL] [Abstract][Full Text] [Related]
14. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
Horisberger A; La Rosa S; Zurcher JP; Zimmermann S; Spertini F; Coukos G; Obeid M
J Immunother Cancer; 2018 Dec; 6(1):156. PubMed ID: 30587227
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
Stroud CR; Hegde A; Cherry C; Naqash AR; Sharma N; Addepalli S; Cherukuri S; Parent T; Hardin J; Walker P
J Oncol Pharm Pract; 2019 Apr; 25(3):551-557. PubMed ID: 29207939
[TBL] [Abstract][Full Text] [Related]
16. [A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1
Antibody-Safety and Effectiveness of Pirfenidone].
Yu H; Li J; Yu L; Cheng X; Han X; Zhang X
Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):519-525. PubMed ID: 34134189
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor-Related Pneumonitis.
Gomatou G; Tzilas V; Kotteas E; Syrigos K; Bouros D
Respiration; 2020; 99(11):932-942. PubMed ID: 33260191
[TBL] [Abstract][Full Text] [Related]
18. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
Li M; Wong D; Vogel AS; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Hepatology; 2022 Mar; 75(3):531-540. PubMed ID: 34709662
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.
Gounant V; Brosseau S; Naltet C; Opsomer MA; Antoine M; Danel C; Khalil A; Cadranel J; Zalcman G
Lung Cancer; 2016 Sep; 99():162-5. PubMed ID: 27565934
[TBL] [Abstract][Full Text] [Related]
20. Pneumonitis From Anti-PD-1/ PD-L1 Therapy.
Balaji A; Verde F; Suresh K; Naidoo J
Oncology (Williston Park); 2017 Oct; 31(10):739-46, 754. PubMed ID: 29083466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
